Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Obtains CHMP Backing For Revlimid Generic In Two Indications

Accord Already Holds Final Approval For Lenalidomide Generic

Executive Summary

Mylan is taking aim at a lucrative oral solid formulation in Europe, with the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending approval for the company’s generic version of Revlimid (lenalidomide) capsules.

You may also be interested in...



Krka, Accord And Xeris Pick Up European Nods

The EMA’s CHMP has recommended granting pan-European marketing authorizations for Krka’s lenalidomide versions of Revlimid and Accord’s sunitinib rival to Sutent, as well as Xeris Pharmaceuticals’ glucagon hybrid rival to Glucagen.

Teligent Announces $140m Operating Loss As Plant Woes Continue

Struggling Teligent underlined the importance of lifting the FDA Warning Letter against its key manufacturing facility in Buena, New Jersey, as its impact slammed the company’s operations last year.

Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data

Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel